phase i study of abbv-383, a bcma×cd3 bispecific antibody, in r/r myeloma
Published 1 year ago • 112 plays • Length 1:14Download video MP4
Download video MP3
Similar videos
-
7:02
using 3-d ultrasonography, deep learning and convolutional neural networks to detect breast cancer
-
1:59
tangible benefit for flt3-itd r/r aml on quizartinib
-
2:37
how to simplify cancer pathology reporting with efrm
-
3:20
phase i trial of a bcma-cd3 bispecific antibody in r/r myeloma
-
0:48
primary results from phase iii augment trial in recurrent indolent lymphomas
-
2:35
exploratory analysis of frontline therapies in revel: a phase 3 trial of ramucirumab in nsclc
-
20:14
apcca2019_019_session 3b: guidelines for care of the patient receiving chemotherapy
-
4:09
quantum-r: quizartinib looks promising for flt3-itd mutated aml
-
2:37
exploratory analysis of frontline therapies in revel: phase 3 trial of ramucirumab in nsclc
-
16:33
clinical burden of flt3 positive aml in saudi arabia
-
1:29
bispecific bcma-cd3 antibody teclistamab is efficacious and tolerable in r/r mm
-
0:54
targeted sequencing in a phase iii trial of luminal breast cancer
-
15:06
cancer2
-
25:01
3mensio ct pre-case planning: redo-tavr with prior sapien 3 (1 of 2)
-
10:15
quizartinib for flt3-mutated aml
-
4:03
chest foundation: tome un respiro (english language)
-
12:07
ai in chemotherapy fernandez v3
-
6:48
durvalumab improves pfs in stage iii lung cancer